Trial Member
Tirzepatide is a new type of double-target hypoglycemic drug with molecular formula C225H348N48O68 and CAS number 2023788-19-2. As a dual agonist of GLP-1 and GIP receptors, it regulates blood glucose by enhancing insulin secretion, inhibiting glucagon production and delaying gastric emptying. It is mainly suitable for the treatment of type 2 diabetes, and clinical trials have shown that it significantly reduces HbA1c levels and has a weight loss effect. The drug, developed by Eli Lilly under the trade name Mounjaro®, is injected subcutaneously once a week. Common side effects include gastrointestinal reactions (eg, nausea, diarrhea). Its innovative mechanism provides a new option for the treatment of metabolic diseases, and is currently exploring indications such as obesity.